J Hum Hypertens. 1990 Dec;4 Suppl 5:19-25.
The effect of verapamil on death, reinfarctions, and major events i.e. reinfarction or death, has been investigated in two Danish double-blind, placebo-controlled verapamil infarction trials DAVIT I and II. DAVIT I, which was an early intervention trial, demonstrated that after six months there was a statistically non-significant reduction of mortality and reinfarction. DAVIT II demonstrated a non-significant reduction of mortality rate (P = 0.11, hazard ratio 0.80, 95% confidence limits 0.61-1.05), a significant reduction of reinfarction rate (P = 0.04, 0.77, 0.58-1.03), and major event rate (P = 0.03, 0.80, 0.64-0.99) in the verapamil group compared with the placebo group. Meta-analyses of DAVIT I (including only patients alive on day eight) and of DAVIT II showed a statistically significant reduction of odds ratio of mortality of 22% (P = 0.04), of reinfarctions of 27% (P = 0.02), and of major events of 21% (P = 0.02). It is concluded that long-term treatment with verapamil after an acute myocardial infarction is associated with a significant reduction in overall mortality, major events, and reinfarction rates.
在两项丹麦双盲、安慰剂对照的维拉帕米心肌梗死试验DAVIT I和DAVIT II中，研究了维拉帕米对死亡、再梗死以及主要事件（即再梗死或死亡）的影响。DAVIT I是一项早期干预试验，结果显示六个月后死亡率和再梗死率在统计学上有不显著的降低。DAVIT II显示维拉帕米组与安慰剂组相比，死亡率有不显著降低（P = 0.11，风险比0.80，95%置信区间0.61 - 1.05），再梗死率有显著降低（P = 0.04，0.77，0.58 - 1.03），主要事件率有显著降低（P = 0.03，0.80，0.64 - 0.99）。对DAVIT I（仅包括第8天存活的患者）和DAVIT II的荟萃分析显示，死亡率的优势比有统计学显著降低22%（P = 0.04），再梗死率降低27%（P = 0.02），主要事件率降低21%（P = 0.02）。结论是急性心肌梗死后长期使用维拉帕米治疗与总体死亡率、主要事件和再梗死率的显著降低相关。
